A quantitative basis for antiretroviral therapy for HIV-1 infection

Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance

(2011) M. E. S. Sampah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs

(2011) L. Shen et al.   Science Translational Medicine

Protease inhibitor monotherapy

(2010) Ignacio Pérez-Valero et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

(2009) Wouter FW Bierman et al.   AIDS

HIV-1 Gag Processing Intermediates Trans-dominantly Interfere with HIV-1 Infectivity

(2009) Barbara Müller et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

(2008) Lin Shen et al.   NATURE MEDICINE